<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021446</url>
  </required_header>
  <id_info>
    <org_study_id>AYA_ASCEND</org_study_id>
    <nct_id>NCT04021446</nct_id>
  </id_info>
  <brief_title>A Supervised Clinic-to-Community Exercise Intervention to Improve Cardiometabolic Health in Survivors of AYA Cancer</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>A Supervised Clinic-to-Community Exercise Intervention to Improve Cardiometabolic Health in Survivors of Adolescent and Young Adult Cancer: The ACSEND Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this clinical trial is to use a novel exercise intervention to improve&#xD;
      cardiometabolic and biopsychosocial health outcomes in overweight/obese sedentary survivors&#xD;
      of AYA cancers at risk for chronic comorbid conditions. The investigator's hypothesis is that&#xD;
      an exercise intervention will improve: cardiometabolic health; body composition; physical&#xD;
      fitness and biopsychosocial outcomes when compared to the attention control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiometabolic health - Insulin Resistance</measure>
    <time_frame>change from baseline to 4 months, to 8 months to 1 year</time_frame>
    <description>insulin resistance estimated by HOMA from a fasting blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiometabolic health - metabolic syndrome waist circumference</measure>
    <time_frame>change from baseline to 4 months, to 8 months to 1 year</time_frame>
    <description>markers of metabolic syndrome, waist circumference via measuring tape (cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiometabolic health - metabolic syndrome blood pressure</measure>
    <time_frame>change from baseline to 4 months, to 8 months to 1 year</time_frame>
    <description>markers of metabolic syndrome, blood pressure via Omron cuff (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>change from baseline to 4 months, to 8 months to 1 year</time_frame>
    <description>fat mass and lean mass via DEXA (reported in lbs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory fitness (Physical Fitness)</measure>
    <time_frame>change from baseline to 4 months, to 8 months to 1 year</time_frame>
    <description>cardiorespiratory fitness via submaximal VO2 max (reported via ml/kg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscular Strength (Physical Fitness)</measure>
    <time_frame>change from baseline to 4 months, to 8 months to 1 year</time_frame>
    <description>muscle strength through multiple repetition maximum (lbs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiometabolic Dysregulation</condition>
  <condition>Young Adult Cancer</condition>
  <condition>Adolescent Cancer</condition>
  <condition>Body Composition</condition>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive the exercise intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will not receive the exercise intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>personalized exercise prescription</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AYA cancer survivors (18-39) Must be 12 months after treatment No metastatic disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Christina Dieli-Conwright</investigator_full_name>
    <investigator_title>Assistant Professor of Research</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

